Taken together, these results constitute genetics-driven evidence suggesting that combination therapy with CETP and SGLT2 inhibitors confers improved protection against hyperglycemia and diabetes risk compared to SGLT2 inhibitors alone. The gene discussed is SLC5A2; the disease is Hyperglycemia.